文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

妇科肿瘤学中宫颈癌和子宫癌免疫组织化学的发展态势:现状与未来方向

The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions.

作者信息

Gupta Sumedha, Ahuja Sana, Kalwaniya Dheer Singh

机构信息

Department of Obstetrics & Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.

Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.

出版信息

Obstet Gynecol Sci. 2024 Sep;67(5):449-466. doi: 10.5468/ogs.24120. Epub 2024 Sep 4.


DOI:10.5468/ogs.24120
PMID:39231489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11424185/
Abstract

Immunohistochemistry (IHC) has become an indispensable tool in routine gynecological pathology, particularly with the advancements in molecular understanding and histological classification of gynecological cancers. This evolution has led to new immunostainings for diagnostic and classification purposes. This review describes the diagnostic utility of IHC in gynecological neoplasms, drawing insights from literature reviews, personal experiences, and research findings. It delves into the application of IHC in resolving morphologically equivocal cases, emphasizing its role in achieving an accurate diagnosis. The selection of appropriate immunomarkers for common scenarios encountered in gynecological pathology aids pathologists in navigating complex cases. Specifically, we focus on cervical and endometrial malignancies, elucidating the molecular rationale behind the use of specific immunohistochemical markers. An updated overview of essential immunohistochemical markers provides knowledge for precise diagnosis and classification of gynecological cancers. This review serves as a valuable resource for clinicians and researchers involved in the management and study of gynecological malignancies, facilitating improved patient care and outcomes.

摘要

免疫组织化学(IHC)已成为妇科常规病理学中不可或缺的工具,尤其是随着对妇科癌症分子理解和组织学分类的进展。这种演变导致了用于诊断和分类目的的新免疫染色方法。本综述描述了免疫组织化学在妇科肿瘤中的诊断效用,借鉴了文献综述、个人经验和研究结果。它深入探讨了免疫组织化学在解决形态学上模棱两可的病例中的应用,强调其在实现准确诊断方面的作用。为妇科病理学中常见情况选择合适的免疫标志物有助于病理学家处理复杂病例。具体而言,我们专注于宫颈和子宫内膜恶性肿瘤,阐明使用特定免疫组化标志物背后的分子原理。对重要免疫组化标志物的最新概述为妇科癌症的精确诊断和分类提供了知识。本综述为参与妇科恶性肿瘤管理和研究的临床医生和研究人员提供了宝贵资源,有助于改善患者护理和治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/c4f58898378c/ogs-24120f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/13d8000f56d7/ogs-24120f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/1e805f9f4896/ogs-24120f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/b511d7d7e73a/ogs-24120f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/c8ae1711523f/ogs-24120f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/2e9b8a28ce6a/ogs-24120f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/86d897af8798/ogs-24120f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/fb627f40f8c8/ogs-24120f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/71baa26e2949/ogs-24120f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/3d26f0ffb2c9/ogs-24120f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/c4f58898378c/ogs-24120f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/13d8000f56d7/ogs-24120f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/1e805f9f4896/ogs-24120f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/b511d7d7e73a/ogs-24120f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/c8ae1711523f/ogs-24120f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/2e9b8a28ce6a/ogs-24120f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/86d897af8798/ogs-24120f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/fb627f40f8c8/ogs-24120f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/71baa26e2949/ogs-24120f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/3d26f0ffb2c9/ogs-24120f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5d1/11424185/c4f58898378c/ogs-24120f10.jpg

相似文献

[1]
The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions.

Obstet Gynecol Sci. 2024-9

[2]
Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios.

J Clin Pathol. 2018-2

[3]
An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology.

Gynecol Oncol. 2018-5-21

[4]
Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.

Ont Health Technol Assess Ser. 2010

[5]
The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Virchows Arch. 2017-12-12

[6]
Application of immunohistochemistry in breast pathology: a review and update.

Arch Pathol Lab Med. 2014-12

[7]
Immunohistochemistry Markers in Ovarian and Fallopian Tube Neoplasms: a Comprehensive Review.

Indian J Surg Oncol. 2024-9

[8]
The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.

Int J Gynecol Pathol. 2021-1

[9]
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].

Zhonghua Fu Chan Ke Za Zhi. 2022-5-25

[10]
Clinical applications of immunohistochemistry in gynecological malignancies.

Int J Gynecol Cancer. 2007

引用本文的文献

[1]
Vaginal Adenocarcinoma: A Review of a Rare Gynecologic Cancer.

Cancers (Basel). 2025-6-25

本文引用的文献

[1]
Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities.

Cancers (Basel). 2024-3-16

[2]
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.

Cancers (Basel). 2023-8-14

[3]
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.

Front Oncol. 2022-10-14

[4]
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.

Int J Gynecol Cancer. 2021-4

[5]
PD-1/PD-L1 pathway: current researches in cancer.

Am J Cancer Res. 2020-3-1

[6]
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

J Thorac Oncol. 2020-4

[7]
Revised FIGO staging for carcinoma of the cervix uteri.

Int J Gynaecol Obstet. 2019-1-17

[8]
Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.

Am J Surg Pathol. 2019-4

[9]
Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.

Gynecol Oncol. 2018-9-24

[10]
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Mod Pathol. 2018-8-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索